Hetrombopag

A medication used to treat thrombocytopenia

Chemical structure of Hetrombopag

Hetrombopag is a medication used primarily for the treatment of thrombocytopenia, a condition characterized by abnormally low levels of platelets in the blood. It is classified as a thrombopoietin receptor agonist, which means it stimulates the production of platelets by activating the thrombopoietin receptor.

Mechanism of Action

Hetrombopag works by mimicking the action of thrombopoietin, a natural hormone that regulates platelet production. It binds to and activates the thrombopoietin receptor on megakaryocytes, the precursor cells in the bone marrow that develop into platelets. This activation leads to increased production and release of platelets into the bloodstream, thereby alleviating the symptoms of thrombocytopenia.

Uses

Hetrombopag is primarily indicated for patients with chronic immune thrombocytopenic purpura (ITP) who have not responded adequately to other treatments. It may also be used in other conditions associated with low platelet counts, such as aplastic anemia and certain types of chemotherapy-induced thrombocytopenia.

Administration

Hetrombopag is administered orally, and the dosage is typically adjusted based on the patient's platelet count and response to the medication. Regular monitoring of platelet levels is essential to ensure the effectiveness of the treatment and to avoid potential complications such as excessive platelet production.

Side Effects

Common side effects of Hetrombopag include headache, fatigue, and nausea. More serious side effects can occur, such as liver function abnormalities and thromboembolic events, which require careful monitoring and management.

Contraindications

Hetrombopag is contraindicated in patients with known hypersensitivity to the drug or any of its components. Caution is advised in patients with liver impairment, as the drug can affect liver function.

Related pages

• Thrombocytopenia
• Thrombopoietin
• Immune thrombocytopenic purpura
• Aplastic anemia